Status:
UNKNOWN
A Real World Study of the Treatment of Gastric Adenocarcinoma With Huachansu
Lead Sponsor:
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Conditions:
Gastric Adenocarcinoma
Eligibility:
All Genders
Brief Summary
To evaluate the efficacy and safety of huachansu oral preparation in the treatment of inoperable locally advanced or advanced metastatic gastric adenocarcinoma, including gastric esophageal adenocarci...
Detailed Description
In this multicenter, controlled, retrospective, real-world study, the original medical records of participants diagnosed with inoperable locally advanced or advanced metastatic gastric adenocarcinoma ...
Eligibility Criteria
Inclusion
- Only patients who meet all the following criteria are included in the study:
- Diagnosed with gastric adenocarcinoma (including gastric esophageal junction adenocarcinoma) by histopathology or cytology at the enrolled centers From January 1, 2014 to December 31, 2019.
- Stage of disease (clinical or pathological stage) is locally advanced or advanced (stage IIIB-IV) .
- The doctor judged that the tumor tissue was unresectable.
- At least two medical records.
- At least one huachansu oral preparation (tablet, capsule) was used during treatment (observation group only) .
Exclusion
- Patients who meet any of the following criteria are not allowed to enter the test:
- Lack of clinical data related to important research indicators (survival).
- Refusal to cooperate with follow-up.
Key Trial Info
Start Date :
July 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05249244
Start Date
July 1 2021
End Date
February 28 2022
Last Update
February 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Anhui Medical University
Hefei, China